Member Info for BuenaVista

Anbd hopefully not a flash in the pan.

It's not quite as straightforward as that.

If it were simply [leaving group-CO2] plus [H2N-drug] forming the peptide-bonded conjugate [leaving group-CO-NH-drug] where the leaving group is always the 5140 that is the leaving group of AVA6000 then it would be technology (about to be) proven as 5140 is being shown to be inert.

However AVA3996 has a different leaving group and that needs to be shown to be inert - as well as the new bortezomib analogue, AVA2727D, needing to be shown to be safe, tolerable and efficacious as it is NOT bortezomib and, you know, the law of unintended consequences...

Why two different leaving groups? And are there any more in the pipeline? I don't know why there are two but this goes back to the original work by Bachovchin where AVA6000 and AVA3996 (named using different research codes) were exemplified. Maybe it's because they both work. Maybe it's because one works best with doxorubicin and the other with the bortezomib analogue. If there aren't going to be any other leaving groups then proving AVA3996's leaving group is inert (or at least not malign) WILL prove the technology and if each platform substrate is FAP specific, then Bob's your uncle and Fanny's your aunt.

There's nothing in the article to say it isn't although "one of the new medications" suggests it's not and is from one of the 'new' classes of drugs and there are in any case numerous trials of 'new' medications ongoing at any one time. But if it were, and the scan showed regression...

I think arranging the star chef, venue, invited audience and media coverage will determine when the event will be. It doesn't need to be announced much beforehand. It could be announced in the morning and appear on some TV programme in the afternoon, for example, or even a few days or weeks later if the celebrity chef has his/her own programme.

The drift down in SP is disappointing but totally normal for a start-up tech company. SPs are always driven up by news and drift down due to lack of more news. A trader's paradise.

SandB wrote "i'm questioning this based on them saying by the end of h2. i've remained patient through may. it's going to be very close between announcing and holding the showcase if they're still aiming for h2."

How much notice do you think they need to give between announcing and holding the event?

@LovableLumax: P1 in the UK, P2 in the USA, P3 unknown unless someone has heard directly from Avacta where that patient was dosed and that's not the sort of information that Avacta would release but RAH says P3 is in the USA and many lemmings then take that as a fact.

Not true Captainstanley. and you won't be able to find a post where I 'pleaded'. All I've said about that twat is that he's a fantasist and he blocked me because I disagreed with him and his darling little ego.

"P3 in the USA" is an unjustified assumption. To my knowledge, the company has not said where the third patient in cohort 5 was dosed. RAH is such a fantasist, FoS. I don't know why peoplke follow it.

You know that pre|CISION relies on a peptide bond (-CO-NH-) that can be cleaved by FAP? What's the structure of Keytruda?

If there is a free -NH2 group that is not conformationally constrained, then yes. Is there?

Not completely true Icecool.

The two biopsies from the patient in cohort 1 (AVA6000 @ 80mg/m²) were both below 400nM (248nM and then 79nM).

Alan did say some time ago that the listed prodrugs that appeared in presentation slides had been made. However, there is now this current vacancy: https://avacta.com/careers/principal-senior-medicinal-chemist/

Are we still seeing the unwinding of positions taken by institutions back in the giveaway 95p fundraise back in October?

Note to developer: Please reprogram HurstBot so that all 'Trading' posts are added to the existing Trading thread and don't clog up the board.

Https://www.voxmarkets.co.uk/articles/q-a-with-avacta-s-ceo-alastair-smith-e87d9e8/

@3:30: "If we reach the MTD in cohort 5 or cohort 6 then we will remain on schedule to complete Phase 1a in the first half of this year. And, to be honest, that's our expectation."

This assumes the cohorts, particularly cohort 5, are not delayed by having to add additional patients - i.e. n>3 - which is fair enough.

Assuming each patient receives 2 doses (so

Maybe Alan could walk around Scale Space with a bell.

"Nine o'clock, and all's well!"

"Ten o'clock, and all's well!"

"Eleven o'clock, and all's well!"

"Twelve o'clock, and I'm going for lunch!"

Honestly, some people.🙄

😂

What's the concern? Avacta don't have any Dx products to make. Avacta doesn't even have any expertise in developing Dx products. Pretty sure Avacta will be learning to walk before attempting a marathon and M&A activity will concentrate initially on extending the distribution network for Dx products that are already on the market.

You heard it here first!

Do the maths.

Only a fool would be out overnight...

@Neutronic, you wrote "My posting history will tell im not one for spreading FUD but i do like to discuss lots of different subjects SUBJECTIVELY ..." I'm sure you meant objectively. Unfortunately some people can't understand or accept any criticism, be it subjective or objective. If I know one thing it's that you never learn anything by rejecting objective criticism.